HBC - Nyheter på rekke og rad !!!!!!!!!!!!!!!!!!
Selskapet satser .....
r. Hermansen is a qualified Orthopaedic surgeon based in Alesund, Norway where he was Head of the Surgical department Ålesund Hospital, Møre and Romsdal Hospital Trust. He has extensive experience in reconstructive joint and spine surgery combined with large scale clinical trial work including his role as Project administrator for the 1,000 patient NORDSTEN-study for the surgical management of spinal stenosis. Along with his medical qualifications Dr. Hermansen holds a PhD from The University of Bergen which assessed different surgical approaches for lumbar spinal stenosis. Dr. Hermansens deep understanding of the musculoskeletal system and clinical trial delivery makes him ideal for the role of Medical Director for Clinical Development at HBC. HBCs marine bone powder CalGo is set to enter clinical development following preclinical work which has shown marked differentiation from other forms of calcium replacement, both for bone mass and strength. In addition to the planned work in bone health (osteoporosis) and joint health (osteoarthritis). Dr. Hermansen is excited by the potential for CalGo in other orthopaedic settings and preclinical work in these areas is set to commence imminently. Osteoporosis is estimated to affect 200 million women globally and osteoarthritis an estimated 250 million individuals globally. CalGo provides all the key elements of healthy bone: type II collagen, calcium hydroxyapaptite (the natural form of bone calcium) and trace elements. HBC believes that it is essential to provide all these key building blocks to provide the greatest impact on both improving and maintaining bone and joint health. As such, HBC is highly focused on the timely delivery of clinical data for CalGo to demonstrate these important benefits and the hiring of Dr. Hermansen is pivotal for this effort. Also, Dr. Hermansen has today indirectly purchased 400,000 shares in HBC at NOK 8.74, equal to the closing price on Tuesday 25 August 2020, through a 3.64 % shareholding in Brilliant Invest AS. For further information about Brilliant Invest AS and its HBC shareholdings, please see https://newsweb.oslobors.no/message/485842 For further information, please contact: Dr. Crawford Currie, Medical R&D at Hofseth BioCare ASA Phone: +44 7968 195497 E-mail: cc@hofsethbiocare.no James Berger, Head of Investor Relations & Strategy at Hofseth BioCare ASA Phone: +41 79 950 1034 E-mail: jb@hofsethbiocare.no About Hofseth BioCare ASA: HBC is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBCs objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market. Hofseth BioCares headquarters are located in Ålesund, Norway with branches in Oslo, Chicago, Menlo Park, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange Axess list with ticker HBC. More information about Hofseth BioCare at www.hofsethbiocare.com and www.facebook.com/hofsethbiocare
r. Hermansen is a qualified Orthopaedic surgeon based in Alesund, Norway where he was Head of the Surgical department Ålesund Hospital, Møre and Romsdal Hospital Trust. He has extensive experience in reconstructive joint and spine surgery combined with large scale clinical trial work including his role as Project administrator for the 1,000 patient NORDSTEN-study for the surgical management of spinal stenosis. Along with his medical qualifications Dr. Hermansen holds a PhD from The University of Bergen which assessed different surgical approaches for lumbar spinal stenosis. Dr. Hermansens deep understanding of the musculoskeletal system and clinical trial delivery makes him ideal for the role of Medical Director for Clinical Development at HBC. HBCs marine bone powder CalGo is set to enter clinical development following preclinical work which has shown marked differentiation from other forms of calcium replacement, both for bone mass and strength. In addition to the planned work in bone health (osteoporosis) and joint health (osteoarthritis). Dr. Hermansen is excited by the potential for CalGo in other orthopaedic settings and preclinical work in these areas is set to commence imminently. Osteoporosis is estimated to affect 200 million women globally and osteoarthritis an estimated 250 million individuals globally. CalGo provides all the key elements of healthy bone: type II collagen, calcium hydroxyapaptite (the natural form of bone calcium) and trace elements. HBC believes that it is essential to provide all these key building blocks to provide the greatest impact on both improving and maintaining bone and joint health. As such, HBC is highly focused on the timely delivery of clinical data for CalGo to demonstrate these important benefits and the hiring of Dr. Hermansen is pivotal for this effort. Also, Dr. Hermansen has today indirectly purchased 400,000 shares in HBC at NOK 8.74, equal to the closing price on Tuesday 25 August 2020, through a 3.64 % shareholding in Brilliant Invest AS. For further information about Brilliant Invest AS and its HBC shareholdings, please see https://newsweb.oslobors.no/message/485842 For further information, please contact: Dr. Crawford Currie, Medical R&D at Hofseth BioCare ASA Phone: +44 7968 195497 E-mail: cc@hofsethbiocare.no James Berger, Head of Investor Relations & Strategy at Hofseth BioCare ASA Phone: +41 79 950 1034 E-mail: jb@hofsethbiocare.no About Hofseth BioCare ASA: HBC is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBCs objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market. Hofseth BioCares headquarters are located in Ålesund, Norway with branches in Oslo, Chicago, Menlo Park, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange Axess list with ticker HBC. More information about Hofseth BioCare at www.hofsethbiocare.com and www.facebook.com/hofsethbiocare
Redigert 21.01.2021 kl 08:40
Du må logge inn for å svare
morgendagen
17.09.2020 kl 12:19
1613
Hva har man mest troen på? Aker Biomarine / krill eller Hofseth biocare/ lakseolje
Biomarine 8,5 mrd kursmål 150 pareto, dagens kurs 97
Hofseth 2,9 mrd kursmål ukjent, dagens kurs 8,68.
Hofseth har også mulig effekt på covid-19, skal testes Q4.
Biomarine 8,5 mrd kursmål 150 pareto, dagens kurs 97
Hofseth 2,9 mrd kursmål ukjent, dagens kurs 8,68.
Hofseth har også mulig effekt på covid-19, skal testes Q4.
Redigert 21.01.2021 kl 08:40
Du må logge inn for å svare
Føre var
01.09.2020 kl 15:14
1866
Ingen som har fått med seg meldingen på newsweb i dag?
Redigert 21.01.2021 kl 08:40
Du må logge inn for å svare
Føre var
01.09.2020 kl 14:16
1900
Tja, kansje den ender godt i pluss i dag, hvem vet?
Om OmeGo kan hjelpe mennesker både med astma og røykelunge så finnes det jo en del kunder der ute i den store verden.
Om OmeGo kan hjelpe mennesker både med astma og røykelunge så finnes det jo en del kunder der ute i den store verden.
Redigert 21.01.2021 kl 08:40
Du må logge inn for å svare
Føre var
01.09.2020 kl 13:43
1925
Vel, for oss som tar en røk i ny og ne så lover jo dette godt:)
Jeg er jo en ivrig leser av Functional Foods in Health and Disease!!
Jeg er jo en ivrig leser av Functional Foods in Health and Disease!!
Redigert 21.01.2021 kl 08:40
Du må logge inn for å svare
BioNord
01.09.2020 kl 13:29
1948
Føre var skrev New study shows potential Ja, alle monner drar:)
Noen som er redd den skal stikke og legger ut en liten sperre på 9,10?
Dette lover bra for de kommende resultatene fra Covid19 studien
Dette lover bra for de kommende resultatene fra Covid19 studien
Redigert 21.01.2021 kl 08:40
Du må logge inn for å svare
Føre var
01.09.2020 kl 13:19
1963
New study shows potential
Ja, alle monner drar:)
Ja, alle monner drar:)
Redigert 21.01.2021 kl 08:40
Du må logge inn for å svare
morgendagen
31.08.2020 kl 17:56
2065
Er jo sikkert ikke all verdens positiv respons på dette covid-19 resultatet.
Men det virker jo som alle begynner å bli mer å mer desperate for en vaksine, eller noe som er positivt.
Blir nok en liten periode der alt blir godtatt å så ser resultatet om hva som funker.
Men det virker jo som alle begynner å bli mer å mer desperate for en vaksine, eller noe som er positivt.
Blir nok en liten periode der alt blir godtatt å så ser resultatet om hva som funker.
Redigert 21.01.2021 kl 08:40
Du må logge inn for å svare
BioNord
31.08.2020 kl 17:03
2085
Sunnmøring
Hva tenker du om denne fremover?
Nå er det vel like før vi før de første resultatene fra Covid19 studien.......8-12 uker var sagt og vi er i 9.uke nå
Hva tenker du om denne fremover?
Nå er det vel like før vi før de første resultatene fra Covid19 studien.......8-12 uker var sagt og vi er i 9.uke nå
Redigert 21.01.2021 kl 08:40
Du må logge inn for å svare
BioNord
27.08.2020 kl 11:56
2196
Du verden der kom jammen meg en melding til og endelig reagerte markedet
HOFSETH BIOCARE ASA: SECURES DISTRIBUTION WITH A GLOBAL RETAILER GIANT IN THE UK, SPAIN, ICELAND, AND ONLINE FOR BRILLIANT SALMON OIL FOR PETS
11:30
Hofseth BioCare ASA (HBC) pet care product Brilliant Salmon Oil, a food and health supplement for dogs and cats, is now available in outlets across the UK, Spain, Iceland and online.
This retail distribution agreement with a global leading club store is an important milestone for HBC in its efforts for global distribution of Brilliant Salmon Oil. The launch has started very successfully, and in-store incentive promotions will start at the end of the month to raise even more awareness.
Kai Morten Thuen, Hofseth BioCare ASAs Head of Sales & Marketing states, This is an honor and great recognition for our company. We are thrilled to enter this retail agreement with one of the most well-renowned global retailers, known for their rigorous quality standards. It further accelerates our growth strategy for our pet care market flagship product, Brilliant Salmon Oil.
Furthermore, in the last three months, HBC has signed up seven more distributors in the US and Canada, covering most of North America. Brilliant Salmon Oil first entered a US store in April of this year and will be available in over 1,000 stores by the end of September. The speed of this success, despite a COVID-19 market slowdown, is seen as very encouraging and outpaces our expectations.
About Brilliant Salmon Oil:
Brilliant Salmon Oil by Hofseth BioCare is produced in Norway using the purest process possible. Due to the unique patented extraction process without boiling or pressing the oil all the natural nutrients in the Atlantic Salmon are preserved. The whole process happening within hours, result in the purest and most transparent oil, completely free of additives. Brilliant contributes to shinier coat, softer paws, as well as helping to prevent cardiovascular disease.
HOFSETH BIOCARE ASA: SECURES DISTRIBUTION WITH A GLOBAL RETAILER GIANT IN THE UK, SPAIN, ICELAND, AND ONLINE FOR BRILLIANT SALMON OIL FOR PETS
11:30
Hofseth BioCare ASA (HBC) pet care product Brilliant Salmon Oil, a food and health supplement for dogs and cats, is now available in outlets across the UK, Spain, Iceland and online.
This retail distribution agreement with a global leading club store is an important milestone for HBC in its efforts for global distribution of Brilliant Salmon Oil. The launch has started very successfully, and in-store incentive promotions will start at the end of the month to raise even more awareness.
Kai Morten Thuen, Hofseth BioCare ASAs Head of Sales & Marketing states, This is an honor and great recognition for our company. We are thrilled to enter this retail agreement with one of the most well-renowned global retailers, known for their rigorous quality standards. It further accelerates our growth strategy for our pet care market flagship product, Brilliant Salmon Oil.
Furthermore, in the last three months, HBC has signed up seven more distributors in the US and Canada, covering most of North America. Brilliant Salmon Oil first entered a US store in April of this year and will be available in over 1,000 stores by the end of September. The speed of this success, despite a COVID-19 market slowdown, is seen as very encouraging and outpaces our expectations.
About Brilliant Salmon Oil:
Brilliant Salmon Oil by Hofseth BioCare is produced in Norway using the purest process possible. Due to the unique patented extraction process without boiling or pressing the oil all the natural nutrients in the Atlantic Salmon are preserved. The whole process happening within hours, result in the purest and most transparent oil, completely free of additives. Brilliant contributes to shinier coat, softer paws, as well as helping to prevent cardiovascular disease.
Redigert 21.01.2021 kl 08:40
Du må logge inn for å svare
BioNord
27.08.2020 kl 08:41
2238
og i dag kommer nok en spennende melding .
Her legges det tilrette for vekst i Kina - veldig spennende
Hofseth BioCare ASA (HBC), today announces the completion of a purchase of 34 % stake in Hong Kong and China based finished products distributor Atlantic Delights Ltd (AD). Over the last five years, AD has established an impressive business of marketing and distributing dietary supplements and nutritional products, based on marine ingredients, in the Asia-Pacific region, including China.
HBC pays approx. USD 700,000 for a 34 % stake in AD and with that ownership, obtains an import license and distribution license in China which would otherwise be very difficult to attain. HBC and AD have already started to merge sales teams to improve and increase distribution reach and achieve other synergies in the Asia Pacific markets. The registration process for the distribution of all other finished products for human nutrition from HBC has also begun and is expected to be approved shortly.
As our most valued customer in China, we have now taken the opportunity to take direct ownership in their business to help grow their sales and distribution strategy. HBC will now leverage ADs existing import and distribution licenses that would otherwise be difficult to attain as outsiders, so this gives us a direct option at taking advantage of the phenomenal opportunity with the Chinese pet care market. China is currently our largest market for Brilliant salmon oil, and we expect its growth to accelerate further from here. All other finished products will also be able to be distributed using this domestic entity going forward which represents another untapped opportunity for us, says CEO Roger Hofseth of Hofseth BioCare.
The acquisition comes at an exciting time for HBC with Brilliant Salmon Oil in particular having phenomenal success in multiple markets and already beating internal company expectations for 2020 with multiple platform launches in Europe and the US and through several distributors covering most of North America. Brilliant Salmon Oil is now the best-selling finished product from HBC.
The last 3 years, AD has a sales CAGR of 330 % and we expect growth to accelerate in the next few years when they join forces with HBCs existing sales team and as they include other products from HBC into their product range.
Her legges det tilrette for vekst i Kina - veldig spennende
Hofseth BioCare ASA (HBC), today announces the completion of a purchase of 34 % stake in Hong Kong and China based finished products distributor Atlantic Delights Ltd (AD). Over the last five years, AD has established an impressive business of marketing and distributing dietary supplements and nutritional products, based on marine ingredients, in the Asia-Pacific region, including China.
HBC pays approx. USD 700,000 for a 34 % stake in AD and with that ownership, obtains an import license and distribution license in China which would otherwise be very difficult to attain. HBC and AD have already started to merge sales teams to improve and increase distribution reach and achieve other synergies in the Asia Pacific markets. The registration process for the distribution of all other finished products for human nutrition from HBC has also begun and is expected to be approved shortly.
As our most valued customer in China, we have now taken the opportunity to take direct ownership in their business to help grow their sales and distribution strategy. HBC will now leverage ADs existing import and distribution licenses that would otherwise be difficult to attain as outsiders, so this gives us a direct option at taking advantage of the phenomenal opportunity with the Chinese pet care market. China is currently our largest market for Brilliant salmon oil, and we expect its growth to accelerate further from here. All other finished products will also be able to be distributed using this domestic entity going forward which represents another untapped opportunity for us, says CEO Roger Hofseth of Hofseth BioCare.
The acquisition comes at an exciting time for HBC with Brilliant Salmon Oil in particular having phenomenal success in multiple markets and already beating internal company expectations for 2020 with multiple platform launches in Europe and the US and through several distributors covering most of North America. Brilliant Salmon Oil is now the best-selling finished product from HBC.
The last 3 years, AD has a sales CAGR of 330 % and we expect growth to accelerate in the next few years when they join forces with HBCs existing sales team and as they include other products from HBC into their product range.
Redigert 21.01.2021 kl 08:40
Du må logge inn for å svare